

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

EPAS ID: PAT8289699

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
CORDEN PHARMA BRUSSELS S.A.	07/16/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	NEUREN PHARMACEUTICALS LIMITED
<b>Street Address:</b>	LEVEL 15 PWC TOWER, 188 QUAY STREET
<b>City:</b>	AUCKLAND
<b>State/Country:</b>	NEW ZEALAND
<b>PROPERTY NUMBERS Total: 2</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17847736
<b>Application Number:</b>	17347135
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Email:</b>	jwalley@sternekessler.com, bcalloway@sternekessler.com
<b>Correspondent Name:</b>	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C
<b>Address Line 1:</b>	1101 K ST. NW, 10TH FLOOR
<b>Address Line 4:</b>	WASHINGTON, D.C. 20005
<b>ATTORNEY DOCKET NUMBER:</b>	4642.0020003
<b>NAME OF SUBMITTER:</b>	MICHAEL F. GROSS III, REG. NO. 64,974
<b>SIGNATURE:</b>	/Michael F. Gross III, #64,974/
<b>DATE SIGNED:</b>	11/21/2023
<b>Total Attachments: 6</b>	
source=12-Suppl-Assignment-CPB-to-NPL-4642-0020003#page1.tif	
source=12-Suppl-Assignment-CPB-to-NPL-4642-0020003#page2.tif	
source=12-Suppl-Assignment-CPB-to-NPL-4642-0020003#page3.tif	
source=12-Suppl-Assignment-CPB-to-NPL-4642-0020003#page4.tif	
source=12-Suppl-Assignment-CPB-to-NPL-4642-0020003#page5.tif	
source=12-Suppl-Assignment-CPB-to-NPL-4642-0020003#page6.tif	

**CORPORATE TO CORPORATE**  
**SUPPLEMENTAL ASSIGNMENT OF PATENTS, APPLICATIONS, AND INVENTIONS**

WHEREAS, Corden Pharma Brussels S.A. (hereinafter termed "ASSIGNOR"), formerly known as Peptisyntha S.A., having an address at 310 rue de Ransbeek, 1120, Brussels, Belgium, is the owner of all of the below-named Inventor's right title and interest in the following patents and patent applications:

Title:	Compositions of Trofinetide
Inventors:	Etienne David Frank Philippe Moniotte, Kruisboogschuttersstraat 6, Vilvoorde, 1800, Belgium; Karel Willy Luc Decroos, Rozebroekstraat 99, Gent, 9040, Belgium; Martin Bernard Catherine Bousmanne, Avenue des Pleiades 53, Woluwe Saint-Lambert, 1200, Belgium; and Cecilia Betti, Rue du Tocsin 14, Bruxelles, 1000, Belgium
Application No.:	US 62/882,998
Attorney Docket No.:	NRNZ-01071US1

WHEREAS, PATENT PROPERTY shall include each and all of the following:

(a) each of the foregoing patents and patent applications therefore and all documents from which any of the above patents and patent applications claim priority and the inventions disclosed therein, and all embodiments of such inventions heretofore assigned to ASSIGNOR [all collectively hereinafter termed "Inventions"];

(b) all rights to apply in any and all countries of the world, expressly including the right to claim priority to the above application(s), for patents, certificates of invention or other governmental grants on said Inventions, including the right to apply for patents pursuant to the International Convention for the Protection of Industrial Property or pursuant to any other convention, treaty, agreement or understanding;

(c) any and all applications filed and any and all patents, certificates of invention or other governmental grants granted on said inventions in each and every country, including each and

18

every application filed and each and every patent granted on any application which is a division, substitution, or continuation, of any of said applications;

(d) each and every reissue or extension of any of said patents;

(e) each and every patent claim resulting from a reexamination certificate for any and all of said patents, and

(f) the right to sue for and all claims for damages, profits or other recovery resulting from infringement, including past infringement, of any of the foregoing.

WHEREAS Neuren Pharmaceuticals Limited (hereinafter termed "ASSIGNEE"), a New Zealand company having Corporate Offices at Level 15 PWC Tower, 188 Quay Street, Auckland, Country of New Zealand, is to acquire from ASSIGNOR the entire rights, title and interest in and to said Patent Property.

NOW THEREFORE, for good and valuable consideration acknowledged by said ASSIGNOR to have been received in full from said ASSIGNEE:

1. In so far as the right to claim priority from said application has not yet been explicitly assigned to ASSIGNEE by the Assignment dated 19 May 2020, ASSIGNOR hereby sells, assigns, transfers and otherwise conveys to ASSIGNEE, and ASSIGNEE's successors, legal representatives and assigns, the entire right, title, and interest in, expressly including the right to claim priority to the above application(s), and to the PATENT PROPERTY.

2. ASSIGNOR further agrees to execute and cause to be executed such additional instruments as may be necessary or desirable to confirm the transfer of rights as herein contemplated, to record the transfer of rights in the United States and throughout the world, and to permit ASSIGNEE, and ASSIGNEE's successors, legal representatives and assigns to enforce the PATENT PROPERTY.

3. This ASSIGNMENT may be executed in counterparts. If this ASSIGNMENT is executed in counterparts, all counterparts together shall be considered to be a single instrument.

Y

IN WITNESS WHEREOF, ASSIGNOR has caused this instrument to be executed by its duly authorized corporate office this 16th day of July 2020 in the Country of BELGIUM.

**ASSIGNOR: CORDEN PHARMA BRUSSELS S.A.**

By: [Signature]  
(Signature)

Name: JAN RAES

Title: MANAGING DIRECTOR

Signature Date: 16 July 2020

(Assignor) Witnessed by: [Signature] 16 July 2020  
Date  
(Assignor) Name (Printed): GOURLET PHILIPPE  
(Assignor) Occupation: Head of Production  
(Assignor) City/Town of Residence: Rebecq

**NOTARY PUBLIC:**

(Assignor) State (or Province) of \_\_\_\_\_  
(Assignor) County (or City) of \_\_\_\_\_  
(Assignor) Country of \_\_\_\_\_

(Assignor) On \_\_\_\_\_, before me,  
\_\_\_\_\_, personally appeared \_\_\_\_\_, personally known to me or proved to me on the basis of satisfactory evidence, to be the person(s) whose name(s) is/are subscribed on the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which person(s) acted, executed the instrument.

WITNESS my hand and official seal.

\_\_\_\_\_  
Signature of Notary Public

\_\_\_\_\_  
Place Notary Seal Above

(Assignor) My Commission Expires: \_\_\_\_\_

(Assignor) Date: \_\_\_\_\_

(Assignor) By: \_\_\_\_\_

*N*

IN WITNESS WHEREOF, ASSIGNEE accepts this Assignment has caused this instrument to be executed by its duly authorized corporate office this 17th day of July 2020 in the Country of Australia.

ASSIGNEE: NEUREN PHARMACEUTICALS LIMITED

By: [Signature]

(Signature)

Name: Jonathan Pitcher

Title: CEO & Company Secretary

Signature Date: 17 July 2020

(Assignee) Witnessed by: [Signature] 17 July 2020

(Assignee) Name (Printed): Jonathan Pitcher Date

(Assignee) Occupation: CEO

(Assignee) City/Town of Residence: Sunderland

NOTARY PUBLIC:

(Assignee) State (or Province) of \_\_\_\_\_)

ss.

(Assignee) County (or City) of \_\_\_\_\_)

(Assignee) Country of \_\_\_\_\_)

(Assignee) On \_\_\_\_\_, before me,

\_\_\_\_\_, personally appeared

\_\_\_\_\_, personally known to me or proved to me on the basis of satisfactory evidence, to be the person(s) whose name(s) is/are subscribed on the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the

instrument the person(s), or the entity upon behalf of which person(s) acted, executed the instrument.

(Assignee) WITNESS my hand and official seal.

\_\_\_\_\_  
Signature of Notary Public

\_\_\_\_\_  
Place Notary Seal Above

(Assignee) My Commission Expires: \_\_\_\_\_

(Assignee) Date: \_\_\_\_\_

(Assignee) By: \_\_\_\_\_